ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,275.38
0.54%
Dow Jones
38,686.32
1.51%
Gold vs US Dollar
2,327.355
0.00%
Brent Oil
81.295
0.00%
Bitcoin
67,728.93
0.01%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. UroGen Pharma Ltd (URGN)

  7. UroGen Pharma Ltd (URGN) News

UroGen Pharma (URGN)

UroGen Pharma Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:URGN
DateTimeSourceHeadlineSymbolCompany
22/05/202413:00Business WireUroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation SummitNASDAQ:URGNUroGen Pharma Ltd
13/05/202413:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:URGNUroGen Pharma Ltd
13/05/202413:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:URGNUroGen Pharma Ltd
13/05/202413:00Business WireUroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business HighlightsNASDAQ:URGNUroGen Pharma Ltd
07/05/202413:00Business WireUroGen Pharma to Participate at Upcoming Investor ConferencesNASDAQ:URGNUroGen Pharma Ltd
05/05/202417:20Business WireNew Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction TherapyNASDAQ:URGNUroGen Pharma Ltd
04/05/202420:20Business WireUroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024NASDAQ:URGNUroGen Pharma Ltd
04/05/202416:50Business WireNew Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal TrialNASDAQ:URGNUroGen Pharma Ltd
03/05/202413:00Business WireUroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024NASDAQ:URGNUroGen Pharma Ltd
17/04/202417:02Business WireUroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial CancersNASDAQ:URGNUroGen Pharma Ltd
15/04/202413:00Business WireUroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerNASDAQ:URGNUroGen Pharma Ltd
03/04/202413:00Business WireUroGen Pharma Files Patent Infringement Action Against Teva PharmaceuticalsNASDAQ:URGNUroGen Pharma Ltd
14/03/202412:00Business WireUroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102NASDAQ:URGNUroGen Pharma Ltd
08/03/202413:00Business WireUroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:URGNUroGen Pharma Ltd
04/03/202413:00Business WireUroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024NASDAQ:URGNUroGen Pharma Ltd
04/03/202412:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:URGNUroGen Pharma Ltd
01/03/202412:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:URGNUroGen Pharma Ltd
26/02/202413:00Business WireUroGen Pharma to Present at TD Cowen 44th Annual Health Care ConferenceNASDAQ:URGNUroGen Pharma Ltd
12/02/202422:47Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:URGNUroGen Pharma Ltd
12/02/202422:43Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:URGNUroGen Pharma Ltd
07/02/202421:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:URGNUroGen Pharma Ltd
06/02/202402:16Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:URGNUroGen Pharma Ltd
06/02/202402:15Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:URGNUroGen Pharma Ltd
03/02/202400:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:URGNUroGen Pharma Ltd
03/02/202400:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:URGNUroGen Pharma Ltd
03/02/202400:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:URGNUroGen Pharma Ltd
03/02/202400:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:URGNUroGen Pharma Ltd
01/02/202415:13Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:URGNUroGen Pharma Ltd
01/02/202414:53Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:URGNUroGen Pharma Ltd
01/02/202413:00Business WireUroGen Pharma to Participate at Upcoming Investor ConferencesNASDAQ:URGNUroGen Pharma Ltd
 Showing the most relevant articles for your search:NASDAQ:URGN

Your Recent History

USOTC
FNNNF
Finnair OYJ (PK)
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved